Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Finquest Securities Pvt Ltd
|
$115.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Glenmark Pharmaceuticals Ltd Announces Demise of Chairman Emeritus
Glenmark Pharmaceuticals Ltd announced that Mr. Gracias Saldanha, Founder and Chairman Emeritus of the Company passed away on July 21, 2012.
Latest Developments for Glenmark Pharmaceuticals Ltd
- Glenmark Pharmaceuticals Ltd Receives Final ANDA Approval For Riluzole Tablets, 50mg
- Glenmark Pharmaceuticals Ltd's Partner Receives Final Approval For Rizatriptan Benzoate
- Glenmark Pharmaceuticals Ltd Receives U.S. FDA Approval For Lamotrigine Tablets
- Glenmark Pharmaceuticals Limited's Molecule 'GRC 17536' For Pain And Respiratory Conditions Successfully Completes Phase I Trials In Europe
Latest Key Developments in Pharmaceuticals
- Biogen Idec Inc And Swedish Orphan Biovitrum AB Presents New Data From Phase 3 Study Of Long-Lasting Hemophilia Factor Candidate ALPROLIX
- Medicines Co Announces Positive Results For Solo II Trial Of Oritavancin In Treatment Of Acute Bacterial Skin And Skin Structure Infections
- OHKI CO LTD Announces Concern of Uncollectible or Delayed Receivables
- CKD Bio Announces Resignation of Co-CEO
- Share this
- Link this
- Digg this
Follow Reuters